Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focusing on cancer therapies - Posts positive interim data in its second preclinical efficacy study of its lead programme BVX001 that treats acute myeloid leukaemia. Bivictrix says that the efficacy study is due to be completed before the end of June, and is an attempt to assess the anti-tumour responses of BVX001 at a dose of 10 kilograms twice-weekly. The study shows that BVX001 demonstrates an 89% tumour regression at day 18 following administration of six out of the total eight planned doses.

Chief Executive Officer Tiffany Thorn: "In a short space of time, we have built a comprehensive preclinical data package, with each new data set providing additional validation of our Bi-Cygni therapeutic approach, moving us one step closer to the clinic and offering additional options for future expansion into other indications."

Current stock price: 13.55 pence, down 3.2% in London on Monday

12-month change: down 37%

By Will Neill, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.